采用DSC-MRI共识采集协议对未经治疗脑转移瘤标准化相对CBV的多中心基准研究
该多中心研究按美国国家共识DSC-MRI协议,在3个中心对49例未经治疗的强化脑转移瘤患者行灌注成像,生成标准化相对CBV(srCBV)图。结果显示全部转移瘤平均srCBV为1.83±1.05,显著低于胶质母细胞瘤的2.67±1.34(P=.0009),但两者均显著高于正常表现白质(0.68±0.18,P<.0001)。
要点
- 共识DSC-MRI协议下脑转移瘤平均srCBV为1.83±1.05,可作为后续研究基准值。
- 脑转移瘤srCBV显著低于胶质母细胞瘤(P=.0009),但显著高于正常表现白质(P<.0001)。
- 肺癌和泌尿生殖系统转移瘤srCBV与胶质母细胞瘤差异有统计学意义(P=.0002和P=.02)。
核心结论
- 采用共识DSC-MRI协议确定了未经治疗脑转移瘤的平均srCBV值,并与正常表现白质和胶质母细胞瘤比较,为遵循国家共识推荐的后续研究设定基准。
研究设计与样本
- 多中心研究,纳入3个中心共49例未经治疗的强化脑转移瘤患者,另以既往研究31例胶质母细胞瘤作对照。
- 采用共识推荐方案:中等翻转角、GRE-EPI采集,先给予预负荷剂量、再行第二次DSC-MRI,钆对比剂剂量均为0.1 mmol/kg。
- 基于增强后T1加权图像或校准差异图(ΔT1图)勾画强化病灶ROI,生成标准化相对CBV(srCBV)定量图。
关键影像表现/征象
- 全部转移瘤平均srCBV为1.83±1.05,胶质母细胞瘤为2.67±1.34,正常表现白质为0.68±0.18。
- 各组织学类型转移瘤srCBV均显著高于正常表现白质(P<.0001)。
诊断标准与关键数值
- 转移瘤平均srCBV 1.83±1.05显著低于胶质母细胞瘤2.67±1.34(P=.0009),两者均显著高于正常表现白质0.68±0.18(P<.0001)。
- 肺癌转移瘤srCBV与胶质母细胞瘤差异有统计学意义(P=.0002),泌尿生殖系统转移瘤srCBV与胶质母细胞瘤差异有统计学意义(P=.02)。
临床应用与阅片要点
- 阅片时可参照本基准srCBV值(转移瘤1.83±1.05、胶质母细胞瘤2.67±1.34、正常表现白质0.68±0.18)辅助鉴别强化病灶。
- 采用共识DSC-MRI协议(中等翻转角、GRE-EPI、预负荷加第二次0.1 mmol/kg剂量)有助于跨中心和时间比较srCBV。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: A national consensus recommendation for the collection of DSC-MRI perfusion data, used to create maps of relative CBV (rCBV), has been recently established for primary and metastatic brain tumors. The goal was to reduce intersite variability and improve ease of comparison across time and sites, fostering widespread use of this informative measure. To translate this goal into practice, the prospective collection of consensus DSC-MRI data and characterization of derived rCBV maps in brain metastases is needed. The purpose of this multisite study was to determine rCBV in untreated brain metastases in comparison to glioblastoma (GBM) and normal-appearing brain by using the national consensus protocol.
MATERIALS AND METHODS: Subjects from 3 sites with untreated enhancing brain metastases underwent DSC-MRI according to a recommended option that uses a midrange flip angle, GRE-EPI acquisition, and the administration of both a preload and second DSC-MRI dose of 0.1 mmol/kg gadolinium-based contrast agent. Quantitative maps of standardized relative CBV (srCBV) were generated and enhancing lesion ROIs determined from postcontrast T1-weighted images alone or calibrated difference maps, termed Δ T1 (dT1) maps. Mean srCBV for metastases were compared with normal-appearing white matter (NAWM) and GBM from a previous study. Comparisons were performed by using either the Wilcoxon signed-rank test for paired comparisons or the Mann-Whitney U nonparametric test for unpaired comparisons.
RESULTS: Forty-nine patients with a primary histology of lung (n = 25), breast (n = 6), squamous cell carcinoma (n = 1), melanoma (n = 5), gastrointestinal (GI) (n = 3), and genitourinary (GU) (n = 9) were included in comparison to GBM (n = 31). The mean srCBV of all metastases (1.83±1.05) were significantly lower (P = .0009) than mean srCBV for GBM (2.67 ± 1.34) with both statistically greater (P < .0001) than NAWM (0.68 ± 0.18). Histologically distinct metastases are each statistically greater than NAWM (P < .0001) with lung (P = .0002) and GU (P = .02) srCBV being significantly different from GBM srCBV.
CONCLUSIONS: Using the consensus DSC-MRI protocol, mean srCBV values were determined for treatment-naïve brain metastases in comparison to normal-appearing white matter and GBM thus setting the benchmark for all subsequent studies adherent to the national consensus recommendation.
引用
- Loizzo SK, Prah MA, Kong MJ, et al. Multisite Benchmark Study for Standardized Relative CBV in Untreated Brain Metastases Using the DSC-MRI Consensus Acquisition Protocol. AJNR Am J Neuroradiol. 2025. PMID: 39389776. doi:10.3174/ajnr.A8531
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。